Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Herpes Zoster 2Spondylitis, Ankylosing 1Psoriasis 1Osteosarcoma 1Neuroblastoma 1Crohn Disease 1Chickenpox 1Arthritis, Rheumatoid 1Arthritis, Psoriatic 1Arthritis 1

Interventions

tofacitinib 7Etanercept 6Methotrexate 3Adalimumab 3secukinumab 2Nivolumab 2sotrastaurin 1sodium luminolate 1ixekizumab 1deucravacitinib 1calcipotriene 1cabozantinib 1baricitinib 1apremilast 1abrocitinib 1Vitamin D 1Vaccines 1Specimen Handling 1Saline Solution 1Platinum Compounds 1Ipilimumab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Exercise 1Eicosapentaenoic Acid 1Docosahexaenoic Acids 1Cholecalciferol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Psoriasis × Herpes Zoster Vaccine × Clear all
NCT02538341 2021-11-23

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

University of Alabama at Birmingham

Phase 2 Completed
617 enrolled 17 charts

Arthritis, Arthritis, Rheumatoid, Crohn Disease, Psoriasis, Spondylitis, Ankylosing, Arthritis, Psoriatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡